Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial

Zahra Kiani,Nadereh Khorsand,Fahimeh Beigi,Gholamreza Askari,Manoj Sharma,Mohammad Bagherniya
DOI: https://doi.org/10.1186/s13063-024-08006-y
IF: 2.728
2024-03-05
Trials
Abstract:Burn injuries are important medical problems that, aside from skin damage, cause a systemic response including inflammation, oxidative stress, endocrine disorders, immune response, and hypermetabolic and catabolic responses which affect all the organs in the body. The aim of this study was to determine the effect of coenzyme Q10 (CoQ10) supplementation on inflammation, oxidative stress, and clinical outcomes in burn patients.
medicine, research & experimental
What problem does this paper attempt to address?
### The Problem the Paper Attempts to Solve This paper aims to explore the effects of coenzyme Q10 (CoQ10) supplementation on inflammation, oxidative stress, and clinical outcomes in burn patients. #### Background Burns are a significant medical issue that not only cause skin damage but also trigger systemic responses, including inflammation, oxidative stress, endocrine disorders, immune responses, and hypermetabolic and catabolic reactions, which affect various organs throughout the body. #### Research Objective The primary objective of this study is to determine whether CoQ10 supplementation can improve inflammatory markers, oxidative stress markers, and clinical outcomes in burn patients. #### Methods This is a double-blind, placebo-controlled randomized clinical trial that included a total of 60 burn patients, randomly divided into two groups: - Experimental group: 100 mg of CoQ10 three times a day (a total of 300 mg/day) for 10 days. - Placebo group: Maltodextrin placebo of the same dosage three times a day for 10 days. The primary evaluation indicators include: - Inflammatory markers: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP); - Oxidative stress markers: Total antioxidant capacity (TAC), malondialdehyde (MDA), superoxide dismutase (SOD) activity; - Other related indicators: Fasting blood glucose (FBG), blood urea nitrogen (BUN), creatinine, white blood cell count (WBC), and body temperature. Secondary evaluation indicators include: - Serum albumin, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), other hematological parameters, blood pressure, oxygen saturation, ICU length of stay, and 28-day mortality rate. #### Results A total of 52 participants completed the trial. At the end of the study, there were no significant differences in CRP and ESR levels between the CoQ10 group and the placebo group (P = 0.550 and P = 0.306). No significant differences were observed for TAC, MDA, and SOD activity either (P = 0.865, P = 0.692, and P = 0.633). However, CoQ10 supplementation significantly increased serum albumin levels (P = 0.031). There were no statistically significant differences in other measured outcomes (P > 0.05). #### Conclusion The results indicate that CoQ10 supplementation does not have a significant effect on inflammatory markers and oxidative stress in burn patients but significantly increases serum albumin levels. Further research is needed to confirm this finding.